Bausch Health Americas, Inc.

Other

Pipeline Programs↗

Distinct drugs in development (Preclinical–Phase 3)

Indications↗

Distinct diseases across all programs

214

Clinical Trials↗

All sponsored trials (all statuses)

Orange Book Patents

Across 12 drugs with upcoming expirations

Pipeline

Pipeline Snapshot

By Phase

5 drugs in development

Approved2

Phase 33

Phase 21

Phase 11

Preclinical2

By Therapeutic Area

top 4

Immunology

545%

Dermatology

218%

Ophthalmology

19%

Neurology

19%

R&D Momentum

54/100

Pipeline Velocity

25/100

Trial Completion Rate

88/100

Pipeline Concentration

29/100

Pipeline Freshness

60/100

Strategic Signals

↗Active in Dermatology but thin pipeline — potential licensing opportunity

Activity

Recent Activity

Last 14 days

Oct 30, 2026

Active, not recruiting

A Phase 2b, Randomized, Double-blind, Placebo-controlled, Parallel Group Study of the Efficacy and Safety of Plecanatide in Children and Adolescents Age 6 to <18 Years of Age With Functional Constipation (FC)

Oct 29, 2026

Completed

A Randomized, Double-Blind, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Rifaximin Soluble Solid Dispersion (SSD) for the Delay of Encephalopathy Decompensation in Cirrhosis

Earlier

Oct 21, 2026TrialA Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-122 in the Treatment of Plaque Psoriasis

Oct 21, 2026TrialA Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle- Controlled, 2-Arm, Parallel Group Comparison Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris

Oct 21, 2026TrialA Phase 3, Multicenter, Double-Blind, Randomized, Vehicle Controlled Clinical Study to Assess the Safety and Efficacy of IDP-118 in the Treatment of Plaque Psoriasis

Oct 21, 2026TrialA Randomized, 12-Week, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Plecanatide in Patients With Irritable Bowel Syndrome With Constipation (IBS-C)

Oct 21, 2026TrialA Phase 3, Multi-Center, Randomized, Double-Blind, Vehicle-Controlled, 2 Arm, Parallel Group Study Comparing the Safety and Efficacy of IDP-120 Gel and IDP-120 Vehicle Gel in the Treatment of Acne Vulgaris

Oct 16, 2026TrialRE-AHFIRM (RandomizEd Study of Larsucosterol in Alcohol-associated Hepatitis to Confirm saFety and effIcacy of tReatMent)

4 more events

Oct 7, 2026TrialA Randomized, Double-Blind, Placebo-Controlled, Multicenter, Dose Ranging Study to Evaluate the Safety, Efficacy, and Pharmacokinetics of Budesonide Rectal Foam BID for 2 Weeks, Followed by QD for 4 Weeks, in Pediatric Patients Aged 5 to 17 Years With Active, Mild to Moderate Distal Ulcerative Colitis

Oct 3, 2026TrialA Phase 4, Open-Label, Multicenter Study Evaluating the Absorption and Systemic Pharmacokinetics and HPA Axis Suppression Potential of Topically Applied IDP-122 Lotion in Pediatric Subjects With Moderate to Severe Plaque Psoriasis

Oct 1, 2026TrialCARE: A CAnadian Real World Evidence Study of Brodalumab in Plaque Psoriasis to Understand the Impact on Quality of Life and Work Productivity

Sep 30, 2026TrialA Double-Blind, Placebo-Controlled, Multicenter Study of Efficacy and Safety of Bupropion Hydrobromide in Adolescents and Children With Major Depressive Disorder

Details

Company Info

Company Overview

—

Mkt Cap

—

Revenue

—

Cash

Patent Expirations

36 patent groups across drugs · Source: FDA Orange Book

DrugExpires

Pipeline

Drug Pipeline

Therapeutic Area

Preclinical

Phase 1

Phase 2

Phase 3

Approved

Dermatology(2 drugs)

—

Dermatology(2 drugs)

Immunology(5 drugs)

—

Immunology(5 drugs)

Neurology(1 drug)

—

Neurology(1 drug)

Ophthalmology(1 drug)

—

Ophthalmology(1 drug)

Unknown / Other(2 drugs)

—

Unknown / Other(2 drugs)

Regulatory

Regulatory Timeline

20217 events

FDAOct 28

Cardizem — DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

Application NDA215252 (NDA)

FDAOct 28

Cardizem Cd — DILTIAZEM HYDROCHLORIDE IN DEXTROSE 5%

Application NDA215252 (NDA)

FDAOct 22

Kenalog — XIPERE

Application NDA211950 (NDA)

FDAOct 22

Azmacort — XIPERE

Application NDA211950 (NDA)

FDAAug 27

Ativan — LOREEV XR

Application NDA214826 (NDA)

FDAFeb 5

Ativan — ATIVAN

Application NDA018140

FDAFeb 5

Ativan — ATIVAN

Application NDA017794

20233 events

FDAMay 18

Miebo — MIEBO

Application NDA216675 (NDA)

FDAJan 13

Ativan — ATIVAN

Application NDA017794

FDAJan 13

Ativan — ATIVAN

Application NDA018140

20244 events

FDAAug 14

Kenalog — KENALOG-10

Application NDA012041

FDAAug 9

Kenalog — KENALOG-40, KENALOG-80

Application NDA014901

FDAJun 5

Kenalog — KENALOG-10

Application NDA012041

FDAJun 5

Kenalog — KENALOG-40, KENALOG-80

Application NDA014901

20256 events

FDAApr 16

Cardizem — CARDIZEM LA

Application NDA021392

FDAApr 16

Cardizem — CARDIZEM LA

Application NDA021392

FDAApr 16

Cardizem — CARDIZEM

Application NDA018602

FDAApr 16

Cardizem — CARDIZEM CD

Application NDA020062

FDAFeb 21

Cardizem — DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Application NDA218038 (NDA)

FDAFeb 21

Cardizem Cd — DILTIAZEM HYDROCHLORIDE IN 0.72% SODIUM CHLORIDE

Application NDA218038 (NDA)

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)